Cargando…

Correction: MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma

Detalles Bibliográficos
Autores principales:	Melaiu, Ombretta, Stebbing, Justin, Lombardo, Ylenia, Bracci, Elisa, Uehara, Norihisa, Bonotti, Alessandra, Cristaudo, Alfonso, Foddis, Rudy, Mutti, Luciano, Barale, Roberto, Gemignani, Federica, Giamas, Georgios, Landi, Stefano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5481151/ https://www.ncbi.nlm.nih.gov/pubmed/28640856 http://dx.doi.org/10.1371/journal.pone.0180317

Ejemplares similares

MSLN Gene Silencing Has an Anti-Malignant Effect on Cell Lines Overexpressing Mesothelin Deriving from Malignant Pleural Mesothelioma
por: Melaiu, Ombretta, et al.
Publicado: (2014)

Variation rs2235503 C > A Within the Promoter of MSLN Affects Transcriptional Rate of Mesothelin and Plasmatic Levels of the Soluble Mesothelin-Related Peptide
por: Silvestri, Roberto, et al.
Publicado: (2020)

Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism
por: De Santi, Chiara, et al.
Publicado: (2017)

Identification of Overexpressed Genes in Malignant Pleural Mesothelioma
por: Morani, Federica, et al.
Publicado: (2021)

Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines
por: Melaiu, Ombretta, et al.
Publicado: (2017)

Comparative proteomic analysis of malignant pleural mesothelioma: Focusing on the biphasic subtype
por: Giusti, Laura, et al.
Publicado: (2016)

Liquid Biopsies from Pleural Effusions and Plasma from Patients with Malignant Pleural Mesothelioma: A Feasibility Study
por: Moretti, Gabriele, et al.
Publicado: (2021)

Big and Free Fractions of Gamma-Glutamyltransferase: New Diagnostic Biomarkers for Malignant Mesothelioma?
por: Foddis, Rudy, et al.
Publicado: (2022)

Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum
por: Creaney, Jenette, et al.
Publicado: (2013)

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
por: Castelletti, Laura, et al.
Publicado: (2021)

Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma
por: Inaguma, Shingo, et al.
Publicado: (2017)

Role of Prosaposin and Extracellular Sulfatase Sulf-1 Detection in Pleural Effusions as Diagnostic Biomarkers of Malignant Mesothelioma
por: Zallocco, Lorenzo, et al.
Publicado: (2022)

Soluble Mesothelin-Related Peptides Levels in Patients with Malignant Mesothelioma
por: Franko, Alenka, et al.
Publicado: (2012)

Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

Evaluation of Soluble Mesothelin-related Peptides and MSLN Genetic Variability in Asbestos-related Diseases
por: Goricar, Katja, et al.
Publicado: (2020)

EIF4G1 and RAN as Possible Drivers for Malignant Pleural Mesothelioma
por: Dell’Anno, Irene, et al.
Publicado: (2020)

Association of MiR-126 with Soluble Mesothelin-Related Peptides, a Marker for Malignant Mesothelioma
por: Santarelli, Lory, et al.
Publicado: (2011)

Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma
por: Dell’Anno, Irene, et al.
Publicado: (2020)

Level of mesothelin expression can indicate the prognosis of malignant pleural mesothelioma
por: Feng, Feifei, et al.
Publicado: (2020)

Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis
por: Tian, Long, et al.
Publicado: (2017)

Increased Levels of C-C Chemokine RANTES in Asbestos Exposed Workers and in Malignant Mesothelioma Patients from an Hyperendemic Area
por: Comar, Manola, et al.
Publicado: (2014)

Tissue expression of lactate transporters (MCT1 and MCT4) and prognosis of malignant pleural mesothelioma (brief report)
por: Dell’Anno, Irene, et al.
Publicado: (2020)

One Third of Malignant Pleural Mesothelioma Shows High Immunohistochemical Expression of MSLN or CXCR4 Which Indicates Potent Candidates for Endo-Radiotherapy
por: Hager, Thomas, et al.
Publicado: (2023)

Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
por: Cui, Ai, et al.
Publicado: (2014)

Hitting the Bull’s-Eye: Mesothelin’s Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma
por: Yeo, Dannel, et al.
Publicado: (2021)

A Drug Screening Revealed Novel Potential Agents against Malignant Pleural Mesothelioma
por: Dell’Anno, Irene, et al.
Publicado: (2022)

A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice
por: Linch, Mark, et al.
Publicado: (2014)

Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin
por: Ak, Guntulu, et al.
Publicado: (2017)

Combination of MiR-103a-3p and Mesothelin Improves the Biomarker Performance of Malignant Mesothelioma Diagnosis
por: Weber, Daniel G., et al.
Publicado: (2014)

Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis
por: Gao, Ruiyue, et al.
Publicado: (2019)

Mesothelin expression remodeled the immune-matrix tumor microenvironment predicting the risk of death in patients with malignant pleural mesothelioma
por: Qualiotto, Aline Nery, et al.
Publicado: (2023)

Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma
por: Porta, Camillo, et al.
Publicado: (2008)

A Glimpse in the Future of Malignant Mesothelioma Treatment
por: Pezzicoli, Gaetano, et al.
Publicado: (2021)

Hyaluronan and N-ERC/Mesothelin as Key Biomarkers in a Specific Two-Step Model to Predict Pleural Malignant Mesothelioma
por: Mundt, Filip, et al.
Publicado: (2013)

A Novel Panel of Serum Biomarkers for MPM Diagnosis
por: Bonotti, A., et al.
Publicado: (2017)

Antimeningococcal Vaccination Coverage Among Healthcare Workers in an Italian University Hospital
por: Gattini, Vittorio, et al.
Publicado: (2021)

Metformin Antagonizes Ovarian Cancer Cells Malignancy Through MSLN Mediated IL-6/STAT3 Signaling
por: Yang, Xu, et al.
Publicado: (2021)

Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1
por: Eguchi, Takashi, et al.
Publicado: (2017)

Switching off malignant mesothelioma: exploiting the hypoxic microenvironment
por: Nabavi, Noushin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ocop0e9ueuudj58asgfms38av9